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Abstract
Objective: Schizophrenia is a severe highly heritable mental disorder. Genetic poly-
morphisms of dopaminergic pathways are related to pathogenesis of drug response.
Hyperprolactinemia (HPRL), a common adverse effect of antipsychotics, is attributed
to blockade of dopamine D2 receptors. Ankyrin Repeat and Kinase Domain con-
taining 1 (ANKK1) gene is closely related to Dopamine Receptor D2 type (DRD2) gene
functioning. We examined whether the functional polymorphism rs2734849 in the
ANKK1 gene is associated with antipsychotic-induced HPRL.
Methods: We recruited 446 patients with schizophrenia from among the Russian
population of the Siberian region. The polymorphism rs2734849 in the ANKK1 gene
was genotyped with The MassARRAY® Analyzer 4 by Agena Bioscience™, using the
kit SEQUENOM Consumables iPLEXGold 384. Genotype and allele frequencies were
compared between groups of schizophrenia patients with and without HPRL using
the χ2 test.
Results: A comparison between schizophrenia patients with and without HPRL rev-
ealed significantly higher frequency of the C allele of the polymorphic variant
rs2734849 in the ANKK1 gene in patients with HPRL as compared to the patients
without it (χ2 = 3.70; p = .05; odds ratio [OR] = 1.30 [0.99–1.69]).
Conclusion: The functional polymorphism rs2734849 in the ANKK1 gene was associ-
ated with HPRL in patients with schizophrenia.
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1 | INTRODUCTION
Schizophrenia is a severe mental disorder characterized by disruptions
in thought processes, perceptions, volition, emotional responsiveness,
cognitive processes, and social interactions. Antipsychotic drugs
targeting dopamine neurotransmission are the principal mean of ther-
apeutic intervention for schizophrenia (Rampino et al., 2019). Hyper-
prolactinemia (HPRL), a common adverse effect of antipsychotic
drugs, is attributed to blockade of dopamine D2 receptors within the
pituitary gland (Peuskens, Pani, Detraux, & De Hert, 2014).
Since genetic variation in gene coding for proteins that cross-talk
with DRD2 at the molecular level are associated with response to anti-
psychotics (Rampino et al., 2019), the ANKK1 gene (Ankyrin Repeat
and Kinase Domain containing 1) is of particular interest. The encoded
protein ANKK1, also known as protein kinase PKK2, belongs to a family
of serine/threonine kinases involved in a number of signal transduction
pathways, including cell proliferation, differentiation, and gene (including
DRD2 gene) transcription (Manning, Whyte, Martinez, Hunter, &
Sudarsanam, 2002; Neville, Johnstone, & Walton, 2004; Ponce
et al., 2009). The most frequently examined in a broad range of psychiat-
ric disorders and personality traits functional polymorphism related to
this gene is the Taq1A (rs1800497) (Dubertret et al., 2004; Fossella et al.,
2006; Ponce et al., 2009; Suchanecka, Grzywacz, & Samochowiec, 2011;
Kenny, Voren, & Johnson, 2013; Nymberg et al., 2014; Treble-Barna
et al., 2017; Persson & Stenfors, 2018). It was initially referred to DRD2
but later was shown to be mapped 10 kB downstream of DRD2 in the
neighboring gene ANKK1 near the termination codon of the DRD2 on
chromosome 11q22-q23 (Dubertret et al., 2010; Neville et al., 2004).
To date, there are inconsistent results from several association
studies of ANKK1 polymorphism with schizophrenia and its clinical
phenotypes (Alfimova et al., 2017, 2018; Arab & Elhawary, 2015;
Eisenstein et al., 2017; Nkam et al., 2017; Parsons et al., 2007; Ponce
et al., 2009; Wishart et al., 2011; Yao, Pan, Ding, Pang, &
Wang, 2015; Zhang et al., 2014). It has been hypothesized that
rs1800497 polymorphism is likely to have a modifying effect rather
than causative effect on schizophrenia (Zhang et al., 2014).
DRD2/ANKK1 TaqIA allele status predicts striatal D2R specific
binding in humans (Eisenstein et al., 2016; Gluskin & Mickey, 2016).
Interestingly, CYP2D6 metabolic activity affects mean antipsy-
chotics daily dose only in the presence of DRD2 Taq1A polymorphic
allele. Subpopulation of schizophrenia inpatients with altered CYP2D6
activity (poor and ultra rapid metabolizers) and when carriers of
Taq1A polymorphisms needs special attention of clinicians in aligning
of antipsychotic treatment (Kurylev et al., 2018).
The preliminary epigenetic findings suggest that methylation
levels at CpG site 387 of ANKK1 may be associated with the treat-
ment response to aripiprazole in patients with schizophrenia. Further-
more, methylation of ANKK1 may affect dopaminergic neural
transmission in the treatment of schizophrenia, and may influence
treatment response (Miura et al., 2018).
Next to rs1800497 another functional polymorphism exists in
ANKK1 (i.e., rs2734849) which causes a nonsynonymous G to A transi-
tion leading to an amino-acid change (arginine to histidine) in C-terminal
ankyrin repeat domain of ANKK1 (Huang et al., 2009). There are far
fewer data on the possible role of this polymorphism in psychiatric disor-
ders. The exact role of SNP rs2734849 in ANKK1 in psychiatric disorders
and drug-induced side effects has yet to be fully characterized.
Using the NF-κB-luciferase reporter assay, Huang et al. (2009)
found that the “A” allele of rs2734849 in ANKK1 had greater suppres-
sion (30%) on NF-κB-regulated luciferase activity than the “G” allele
of rs2734849 indicating rs2734849 to be a functional polymorphism.
In a protein sequence alignment and crystal structure comparison with
a 12-ankyrin repeat domain (Michaely, Tomchick, Machius, &
Anderson, 2002), they found that the residue at 490 position resides
on the surface of protein, a prerequisite for its involvement in mediat-
ing protein–protein interaction in the signal-transduction processes
leading to inhibition of NF-κB activity.
SNP rs2734849 in ANKK1 is functional in yielding differential
suppression of NF-κB-regulated gene expression. Since transcription
factor NF-κB is a necessary and sufficient signal factor to induce
DRD2 expression (Bontempi et al., 2007; Fiorentini et al., 2002), this
suggests that variants of ANKK1, specifically rs2734849, may function
to affect DRD2 expression (Huang et al., 2009).
Since dopamine inhibits prolactin secretion by binding to D2
receptors expressed on the cell membrane of the anterior pituitary
lactotrophs, we hypothesized that ANKK1 polymorphism modulation
of DRD2 expression can be involved in the mechanisms of HPRL
induced by antipsychotics due to their high affinity for the D2 recep-
tor. In this study we investigated the association of ANKK1
rs2734849 polymorphism with antipsychotic-induced HPRL in
Russian patients with schizophrenia.
2 | MATERIALS AND METHODS
In this study, 446 patients (225 female/221 male) with schizophrenia
were included from three psychiatric hospitals in Tomsk, Kemerovo,
and Chita oblasts in Siberia, Russian Federation.
The study population and methods applied were previously
described by Ivanova, Osmanova, Boiko, et al., 2017, Ivanova,
Osmanova, Freidin, et al., 2017. Patients could participate if they had
a clinical diagnosis of schizophrenia according to ICD-10 (F20) and
were between 18 and 75 years old. Exclusion criteria were a non-
Caucasian physical appearance (e.g., Mongoloid, Buryats, or
Khakassians), pregnancy, relevant gynecological and endocrine (thy-
roid) disorders, organic brain disorders (e.g., epilepsy, Parkinson's dis-
ease) or relevant pharmacological withdrawal symptoms.
The study procedures were reviewed and approved by the Local
Bioethics Committee of the Mental Health Research Institute. The study
was recorded under protocol number N63/7.2014. Patients were
included after providing written informed consent. None of the partici-
pants was compromised in their capacity to consent; therefore, consent
from the next of kin was not recommended by the ethics committee. All
works were carried out in accordance with The Code of Ethics of the
World Medical Association (Declaration of Helsinki 1975, revised in For-
taleza, Brazil, 2013) for experiments involving humans.
2 of 8 FEDORENKO ET AL.
Depending on the presence of HPRL (vide infra) this group of
patients with schizophrenia was divided into two subgroups:
227 patients with HPRL and 219 patients without HPRL.
Patients were treated with conventional and/or atypical antipsy-
chotic drugs in both oral and/or long-acting formulations. One hundred
ninety-one patients received conventional antipsychotics. Haloperidol
was the most commonly used conventional antipsychotic drug
(110 patients). Other conventional antipsychotics included oral chlor-
promazine (CPZ), chlorprothixene, trifluoperazin, and zuclopenthixol,
and/or long-acting formulations of haloperidol, zuclopenthixol, and
flupenthixol. Atypical antipsychotics were used by 176 patients and
included risperidone, clozapine, quetiapine, olanzapine, amisulpride,
paliperidone, and sertindole. A total of 79 patients used various combi-
nations of classical and atypical drugs. All dosages were converted into
CPZ equivalents (CPZeq) to compare the antipsychotic exposure
(Andreasen, Pressler, Nopoulos, Miller, & Ho, 2010).
2.1 | Sampling
Blood samples for DNA extraction and prolactin determination were
obtained after 8 hr of overnight fasting. For women of reproductive
age, blood was, when possibly, taken in the follicular phase of the
menstrual cycle. Blood samples for DNA extraction were collected in
EDTA tubes and stored at −20C until DNA isolation. Tubes with clot
activator (CAT) were used to obtain serum for measuring prolactin
concentrations (BD Vacutainer). The samples were centrifuged for
30 min at 1,500 rpm at 4C to obtain serum.
2.2 | Biochemical analysis
2.2.1 | Prolactin concentration
An accuBind ELISA Microwells kit (Monobind Inc., USA) was used to
measure the prolactin concentration. The sensitivity of the used ELISA
kit was 0.004 ng/well, what is equivalent to a sample prolactin
concentration of 0.150 ng/ml. The upper limits for a normal prolactin
concentration were set at ≤20 ng/ml for men and at ≤ 25 ng/ml for
non-pregnant, non-nursing women. These criteria for HPRL were con-
firmed in literature (Kelly et al., 2013; Peuskens et al., 2014).
2.2.2 | DNA analysis
A standard phenol–chloroform micro method (as described by Ivanova
et al., 2012) was used to isolate DNA from the leukocytes in the
whole peripheral blood samples after pre-freezing of the blood.
Genotyping for ANKK1 rs2734849 was carried out on the
MassARRAY® Analyzer 4 (Agena Bioscience™) using the set
SEQUENOM Consumables iPLEX Gold 384. DNA sample prepara-
tion for SEQUENOM MassARRAY® Analyzer 4 includes several
steps: a standard PCR reaction to obtain the amplification products,
a shrimp alkaline phosphatase reaction to neutralize the unin-
corporated dNTPs in the amplification products, the PCR iPLEX
Gold extension reaction, and then placing the samples on a special
chip (SpectroCHIP Array) using NanoDispenser RS1000 prior to
loading them into the analyzer.
TABLE 1 Demographic and clinical characteristics of patients with schizophrenia (n = 446)
Trait All (446) Male (221) Female (225) p-valuea
Age (mean ± SD) 42.1 ± 12.4 37.8 ± 11.9 45.2 ± 13.9 p < .0001
Duration of disease,
years Median (IQR)
13 (6; 22) 11 (5; 18) 15 (7; 26) p < .0001
Daily dose of antipsychotics in
CPZeq Median (IQR)
425 (240; 750) 500 (300; 750) 372 (200; 750) p = .003
Prolactin ng/ml Median (IQR) 23.32 (13.12; 49.96) 18.18 (10.61; 32.47) 34.89 (15.50; 65.03) p < .0001
Abbreviations: CPZeq, chlorpromazine equivalents; IQR, interquartile range.
aCalculated with either the t-test or the Mann–Whitney U test, as appropriate.
TABLE 2 Frequencies of genotypes and alleles of ANKK1 rs2734849 in schizophrenia patients with and without HPRL (n = 439)
Genotypes, alleles Patients with HPRL n (%) Patients without HPRL n (%)
OR
χ2 pValue 95% CI
СС 54 (24.3%) 40 (18.4%) 1.42 0.90–2.25 3.65 .16
CТ 110 (49.5%) 105 (48.4%) 1.05 0.72–1.52
ТТ 58 (26.1%) 72 (33.2%) 0.71 0.47–1.08
С 218 (49.1%) 185 (42.6%) 1.30 0.99–1.69 3.70 .05
Т 226 (50.9%) 249 (57.4%) 0.77 0.59–1.01
Abbreviations: 95% confidence interval; ANKK1, Ankyrin Repeat and Kinase Domain containing 1; HPRL, Hyperprolactinemia; OR, odds ratio.
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2.3 | Statistics
Data processing and analysis were performed in the Statistical
Package for Social Science, version 20.0. The deviation from the
Hardy–Weinberg equilibrium was tested with the χ2 test. To
describe the results, frequency distribution tables were used for
categorical variables. In the analysis of categorical variables, the
Fisher's exact test was used for the univariate analysis to evaluate
the HPRL factors associated to the polymorphism. Differences
were considered significant at p ≤ .05. The adjusted odds ratio




We studied 446 Russian patients (225 female/221 male) with schizo-
phrenia from the Siberian region (Tomsk, Kemerovo, and Chita
oblasts). The baseline characteristics of the population are presented
in Table 1.
The median dosage of antipsychotic drugs was 425 CPZ equiva-
lents daily and the mean age of the patients was 41.5 years. In gen-
eral, the mean duration of schizophrenia was 15 years. One hundred
ninety-one Patients were treated with conventional antipsychotics
(42.8%), 176 patients with atypical antipsychotics (39.5%) and 79 with
a combination of conventional and atypical antipsychotics (17.7%).
Assuming a lower limit for the presence of HPRL at >25 ng/ml for
females and >20 ng/ml for males (Kelly et al., 2013; Peuskens
et al., 2014), 227 of the 446 patients suffered from HPRL and
219 patients were without HPRL.
3.2 | Association of ANKK1 rs2734849 with HPRL
in the total group of patients with schizophrenia
Of a total group of 446 schizophrenia patients, genotyping results
were obtained in 439 patients. The frequency of the rs2734849*С
allele of the ANKK1 gene in the total group was significantly higher in
patients with HPRL compared to patients with normal level of prolac-
tin (Table 2; χ2 = 3.7; p = 05; OR 1.30; 95%Cl: 0.99–1.69). When this
group was divided by gender, the rs2734849*С allele of ANKK1 was
found to be a relative risk factor for antipsychotic-induced HPRL in
female patients only (Table 3; χ2 = 4.17; p = .04; OR 1.49; 95%Cl:
1.02–2.18). No statistically significant associations between ANKK1
rs2734849 and HPRL were observed in the subgroup of male patients
with schizophrenia (Table 4).
The analysis of the distribution of prolactin levels depending on
the ANKK1 rs2734849 genotypes in patients with schizophrenia did
not reveal any statistical differences although there was a tendency
TABLE 3 Frequencies of genotypes and alleles of ANKK1 rs2734849 in female schizophrenia patients with and without HPRL
Genotypes, alleles Patients with HPRL, n (%) Patients without HPRL, n (%)
OR
χ2 pValue 95% CI
CC 31 (25.0) 14 (14.9) 1.90 0.95–3.83 4.43 .10
CT 64 (51.6) 49 (52.1) 0.98 0.57–1.68
TT 29 (23.4) 31 (33.0) 0.62 0.34–1.13
C 126 (50.8) 77 (41.0) 1.49 1.02–2.18 4.17 .04
T 122 (49.2) 111 (59.0) 0.67 0.46–0.98
Abbreviations: 95% confidence interval; ANKK1, Ankyrin Repeat and Kinase Domain containing 1; HPRL, Hyperprolactinemia; OR, odds ratio.
TABLE 4 Frequencies of genotypes and alleles of ANKK1 rs2734849 in male schizophrenia patients with and without HPRL
Genotype, alleles Patients with HPRL n (%) Patients without HPRL n (%)
OR
χ2 рValue 95% CI
CC 23 (23.5) 26 (21.1) 1.14 0.61–2.16 0.39 .82
CT 46 (46.9) 56 (45.5) 1.06 0.62–1.80
TT 29 (29.6) 41 (33.3) 0.84 0.47–1.49
C 92 (46.9) 108 (43.9) 1.13 0.78–1.65 0.41 .52
T 104 (53.1) 138 (56.1) 0.88 0.61–1.29
Abbreviations: 95% confidence interval; ANKK1, Ankyrin Repeat and Kinase Domain containing 1; HPRL, Hyperprolactinemia; OR, odds ratio.
TABLE 5 The distribution of prolactin levels depending on the
ANKK1 rs2734849 genotypes in patients with schizophrenia, (ng/ml)
Genotypes N Prolactin levels, me (Q1, Q3) H р
CC 94 25.12 (13.53; 46.12) 5.20 .07
CT 215 24.40 (13.96; 57.78)
TT 130 18.36 (10.49; 44.73)
Abbreviation: ANKK1, Ankyrin Repeat and Kinase Domain containing 1.
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(p = .07) towards higher prolactin levels in patients with schizophrenia
carrying CC and CT genotypes (Table 5).
3.3 | Association of ANKK1 rs2734849 with HPRL
in the subgroup of schizophrenia patients treated with
the risperidone/paliperidone
Due to the fact that, HPRL is significantly more common in patients
receiving risperidone/paliperidone, the next step was the analysis in
the subgroup of patients using the risperidone/paliperidone (n = 75).
No statistically significant associations between ANKK1
rs2734849 and HPRL were found in the subgroup of patients
with schizophrenia treated with the risperidone/paliperidone
(Table 6).
4 | DISCUSSION
A large number of individual genetic association studies have found
that the TaqIA SNP in ANKK1 is linked to psychiatric disorders (Ponce
et al., 2009).
In this study, we investigated the association between functional
polymorphism rs2734849 in ANKK1 gene and antipsychotic-induced
HPRL in Russian patients with schizophrenia from the population of
Siberia. For the first time we demonstrate that allele rs2734849*T of
ANKK1 gene mitigates the risk of antipsychotic-induced HPRL in
schizophrenia suggesting for a protective effect against developing
this side effect, whereas carriage of the rs2734849*С allele was a rel-
ative risk factor for antipsychotic-induced HPRL in schizophrenia. Our
results support the involvement of ANKK1 rs2734849 into pathogen-
esis of antipsychotic-induced HPRL in schizophrenia, although the
underlying molecular mechanisms are not clear.
ANKK1 and DRD2 genes belong to the same gene cluster, the
NTAD cluster, an ancient cluster of which genes are apparently co-
regulated and may have emerged when the central nervous system
became more complex (Feistauer, Vitolo, Campagnolo, Mattevi, &
Almeida, 2018; Mota, Araujo-Jnr, Paix~ao-Côrtes, Bortolini, &
Bau, 2012). A few in vitro studies with ANKK1 gene mRNAs and pro-
teins were able to show the potential connection between this gene
and the dopaminergic system (Feistauer et al., 2018; Garrido
et al., 2011; Hoenicka et al., 2007).
There are data about ANKK1 rs2734849 to be functional in yielding
differential suppression of NF-κB-regulated gene expression. Since tran-
scription factor NF-κB is a necessary and sufficient signal to induce
DRD2 expression (Bontempi et al., 2007; Fiorentini et al., 2002), variants
of ANKK1, specifically rs2734849, may affect DRD2 expression (Huang
et al., 2009). These findings align with the results that DRD2/ANKK1
gene polymorphisms alter the density of dopamine receptors (Stelzel,
Basten, Montag, Reuter, & Fiebach, 2010).
It is known that dopamine holds a predominant role in the regula-
tion of prolactin secretion. It directly inhibits the basally high-
secretory tone of the anterior pituitary lactotrophs by binding to D2
receptors expressed on their cell membrane resulting in a reduction of
prolactin exocytosis. All typical antipsychotic medications are associ-
ated with sustained HPRL due to their high affinity for the D2 recep-
tor and their slow dissociation from the receptor once bound, but
atypicals differ quite dramatically in their propensity causing pro-
longed high prolactin levels (Fitzgerald & Dinan, 2008). As HPRL
directly depends upon the functioning of DRD2 receptors on
mammatrophic cells of the anterior pituitary gland (Peuskens
et al., 2014), altered functionality of these receptors (particularly
altered expression) is more likely to be observed.
Previously in the same sample of patients we studied a set of
41 SNPs of genes encoding the dopamine receptors DRD1, DRD2,
DRD3, DRD4, the dopamine transporter SLC6A3, and dopamine
catabolizing enzymes MAOA and MAOB (Fedorenko et al., 2017;
Osmanova et al., 2019). No associations were found between the
DRD2 gene polymorphism and the antipsychotic-induced HPRL in
patients with schizophrenia. We have demonstrated the MAOB
rs1799836 to be a potential risk factor for HPRL in men in the total
group (Osmanova et al., 2019).
In the current study we hypothesize that in the total group of
patients with schizophrenia those who carry rs2734849*С allele of
ANKK1 gene have higher density of D2 receptors on the anterior pitu-
itary lactotrophs resulting in HPRL induced by antipsychotics due to
their high affinity for the D2 receptors.
Risperidone is known to elevate prolactin due to its higher
peripheral-to-central dopamine receptor potency (Fitzgerald & Dinan,
2008); Geers et al., 2020). Earlier in the same sample of patients we
TABLE 6 Analysis of association between HPRL and ANKK1 rs2734849 in patients with schizophrenia from risperidone/paliperidone
group (n = 75)
Genotype, alleles Patients with HPRL n (%) Patients without HPRL n (%)
OR
χ2 рValue 95% CI
CC 14 (23.7) 3 (18.8) 1.35 0.34–5.42 2.58 .28
CT 28 (47.5) 5 (31.3) 1.99 0.61–6.43
TT 17 (28.8) 8 (50.0) 0.40 0.13–1.25
C 56 (47.5) 11 (34.4) 1.72 0.76–3.89 1.74 .19
T 62 (52.5) 21 (65.6) 0.58 0.26–1.31
Abbreviations: 95% confidence interval; ANKK1, Ankyrin Repeat and Kinase Domain containing 1; HPRL, Hyperprolactinemia; OR, odds ratio.
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have found that the rs40184 and rs3863145 variants in SLC6A3 gene
appeared to be associated with HPRL in the subgroup of patients
using the risperidone/paliperidone, but not with HPRL induced by
other antipsychotic drugs (Osmanova et al., 2019). However, when
only patients treated with risperidone/paliperidone were studied, no
significant association was found with ANKK1 rs2734849 polymor-
phism (Table 6). Another limitation of the study might be our reluc-
tance to analyze genotyping data of ANKK1 in combination with other
genes. We genotyped a few other genes in much the same patient
sample and in the same run (Geers et al., 2020; Ivanova, Osmanova,
Freidin, et al., 2017; Osmanova et al., 2019), but this analysis would
be insufficiently extensive and hypothesis-driven. Our results extend
previous findings about association of ANKK1 with antipsychotic-
induced side effects.
5 | CONCLUSION
The results of this study indicate that the prevalence of antipsychotic-
induced HPRL in Russian patients with schizophrenia is higher in car-
riers of rs2734849*С allele of ANKK1 gene whereas allele
rs2734849*T of ANKK1 gene has a protective effect against
antipsychotic-induced HPRL in this sample. Further investigation will
be required to develop a better understanding of the mechanisms by
which ANKK1 gene polymorphism influence the drug-induced side
effects in schizophrenia.
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